Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 89 for:    DESVENLAFAXINE

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00798707
Recruitment Status : Completed
First Posted : November 26, 2008
Results First Posted : June 6, 2011
Last Update Posted : June 10, 2011
Sponsor:
Information provided by:
Pfizer

Brief Summary:
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) Drug: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 709 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder
Study Start Date : December 2008
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Desvenlafaxine succinate sustained-release 25 mg Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
25 mg tablet, once daily dosing for 8 weeks

Experimental: Desvenlafaxine succinate sustained-release 50 mg Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
50 mg tablet, once daily dosing for 8 weeks

Placebo Comparator: Placebo Drug: placebo
Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.




Primary Outcome Measures :
  1. Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET) [ Time Frame: Baseline and Week 8 (or ET) ]
    HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.


Secondary Outcome Measures :
  1. Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET) [ Time Frame: Week 8 (or ET) ]
    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.

  2. Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET) [ Time Frame: Baseline and Week 8 (or ET) ]
    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.

  3. Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET) [ Time Frame: Baseline and Week 8 (or ET) ]
    MADRS measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  4. Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET) [ Time Frame: Baseline and Week 8 (or ET) ]
    HAM-D6: a standardized, clinician-administered rating scale that assesses 6 items characteristically associated with major depression and is a subset of HAM-D17. HAM-D6 score ranges from 0-22. The scale uses HAM-D17 items: 1, 2, 7, 8, 10 and 13. Item 13 is scored 0-2 and all others are scored 0-4.

  5. Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET) [ Time Frame: Week 8 (or ET) ]
    A HAM-D17 responder was defined as a participant with a 50% or greater decrease from baseline in HAM-D17 score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.

  6. Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET) [ Time Frame: Week 8 (or ET) ]
    Remission was defined as a HAM-D17 score of less than or equal to 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.

  7. Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET) [ Time Frame: Week 8 (or ET) ]
    A MADRS responder was defined as a participant with a 50% or greater decrease from baseline in MADRS score. It measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

  8. Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET) [ Time Frame: Week 8 (or ET) ]
    CGI-I responder was defined as a participant with a score of 1 (very much improved) or 2 (much improved) on the CGI-I. CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)
  • Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of >= 20
  • Clinical Global Impressions Scale-Severity (CGI-S) score of >= 4

Exclusion Criteria:

  • Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline
  • Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00798707


  Hide Study Locations
Locations
Layout table for location information
United States, California
Pfizer Investigational Site
Arcadia, California, United States, 91007
Pfizer Investigational Site
Beverly Hills, California, United States, 90210
Pfizer Investigational Site
Cerritos, California, United States, 90703
Pfizer Investigational Site
Garden Grove, California, United States, 92845
Pfizer Investigational Site
Los Alamitos, California, United States, 90720
United States, Florida
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33702
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30328
Pfizer Investigational Site
Smyrna, Georgia, United States, 30080
United States, Illinois
Pfizer Investigational Site
Libertyville, Illinois, United States, 60048
United States, Ohio
Pfizer Investigational Site
Dayton, Ohio, United States, 45408
United States, Rhode Island
Pfizer Investigational Site
East Providence, Rhode Island, United States, 02914
United States, South Carolina
Pfizer Investigational Site
Columbia, South Carolina, United States, 29201
United States, Tennessee
Pfizer Investigational Site
Memphis, Tennessee, United States, 38117
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75230
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Washington
Pfizer Investigational Site
Kirkland, Washington, United States, 98033
Pfizer Investigational Site
Seattle, Washington, United States, 98104
United States, Wisconsin
Pfizer Investigational Site
Brown Deer, Wisconsin, United States, 53223
Japan
Pfizer Investigational Site
Nagoya, Aichi, Japan, 4530015
Pfizer Investigational Site
Toyoake, Aichi, Japan, 4701192
Pfizer Investigational Site
Noda, Chiba, Japan, 2780033
Pfizer Investigational Site
Kitakyusyu, Fukuoka, Japan, 8020006
Pfizer Investigational Site
Kitakyusyu, Fukuoka, Japan, 8078555
Pfizer Investigational Site
Shirakawa, Fukushima, Japan, 9610021
Pfizer Investigational Site
Fujioka, Gunma, Japan, 3750017
Pfizer Investigational Site
Kumagaya, Gunma, Japan, 3600032
Pfizer Investigational Site
Hatsukaichi, Hiroshima, Japan, 7380023
Pfizer Investigational Site
Kure, Hiroshima, Japan, 7370023
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 0028029
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 0040052
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 0600061
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 600042
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 630061
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 630804
Pfizer Investigational Site
Kobe, Hyogo, Japan, 6530841
Pfizer Investigational Site
Kanazawa, Ishikawa, Japan, 9208650
Pfizer Investigational Site
Minamiashigara, Kanagawa, Japan, 2500136
Pfizer Investigational Site
Yokohama, Kanagawa, Japan, 2200004
Pfizer Investigational Site
Yokohama, Kanagawa, Japan, 2210835
Pfizer Investigational Site
Yokohama, Kanagawa, Japan, 2250012
Pfizer Investigational Site
Yatsushiro, Kumamoto, Japan, 8660043
Pfizer Investigational Site
Matsumoto, Nagano, Japan, 3908510
Pfizer Investigational Site
Sakai, Osaka, Japan, 5900018
Pfizer Investigational Site
Kanzaka, Saga, Japan, 8420192
Pfizer Investigational Site
Misato, Saitama, Japan, 3410018
Pfizer Investigational Site
Kusatsu, Shiga, Japan, 5250037
Pfizer Investigational Site
Bunkyo, Tokyo, Japan, 1120012
Pfizer Investigational Site
Chiyoda, Tokyo, Japan, 1000006
Pfizer Investigational Site
Chiyoda, Tokyo, Japan, 1018643
Pfizer Investigational Site
Itabashi, Tokyo, Japan, 1730004
Pfizer Investigational Site
Katsushika, Tokyo, Japan, 1250041
Pfizer Investigational Site
Kodaira, Tokyo, Japan, 1858551
Pfizer Investigational Site
Minato, Tokyo, Japan, 1070052
Pfizer Investigational Site
Nakano, Tokyo, Japan, 1640012
Pfizer Investigational Site
Setagaya-ku, Tokyo, Japan, 1540004
Pfizer Investigational Site
Setagaya, Tokyo, Japan, 1540012
Pfizer Investigational Site
Shibuya, Tokyo, Japan, 1500001
Pfizer Investigational Site
Shibuya, Tokyo, Japan, 1510053
Pfizer Investigational Site
Shinagawa, Tokyo, Japan, 1410021
Pfizer Investigational Site
Shinagawa, Tokyo, Japan, 1410022
Pfizer Investigational Site
Shinagawa, Tokyo, Japan, 1420021
Pfizer Investigational Site
Shinjyuku, Tokyo, Japan, 1600023
Pfizer Investigational Site
Suginami, Tokyo, Japan, 1660003
Pfizer Investigational Site
Taito, Tokyo, Japan, 1100003
Pfizer Investigational Site
Toshima, Tokyo, Japan, 1700002
Pfizer Investigational Site
Meguro, Toyko, Japan, 1520012
Pfizer Investigational Site
Ube, Yamaguchi, Japan, 7558505
Pfizer Investigational Site
Fukuoka, Japan, 8100001
Pfizer Investigational Site
Fukuoka, Japan, 8100041
Pfizer Investigational Site
Fukushima, Japan, 9600102
Pfizer Investigational Site
Hiroshima, Japan, 7310121
Pfizer Investigational Site
Kumamoto, Japan, 8618002
Pfizer Investigational Site
Kumamoto, Japan, 8620909
Pfizer Investigational Site
Kyoto, Japan, 6168421
Pfizer Investigational Site
Osaka, Japan, 5420006
Pfizer Investigational Site
Saitama, Japan, 33000062
Pfizer Investigational Site
Saitama, Japan, 3390057
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc
ClinicalTrials.gov Identifier: NCT00798707     History of Changes
Other Study ID Numbers: 3151A1-3359
B2061003
3151A1-3359-WW
First Posted: November 26, 2008    Key Record Dates
Results First Posted: June 6, 2011
Last Update Posted: June 10, 2011
Last Verified: June 2011
Keywords provided by Pfizer:
Major Depressive Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Desvenlafaxine Succinate
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents
Psychotropic Drugs